Stryker, the American medical technology corporation, has acquired a $400 million stake in Cambridge-based CMR Surgical, securing an exclusive option to purchase the remainder of the company in the future. The transaction is estimated to give Stryker an approximately 10 percent ownership interest in CMR, valuing the UK surgical robotics firm at around $4 billion.
As part of the agreement, Stryker will serve as CMR’s exclusive sales agent for its Versius surgical robotics portfolio within the United States, the world’s largest healthcare market. Additionally, a Stryker executive is set to join CMR’s board of directors. The investment follows a trend of U.S. companies increasing their stakes in innovative British technology firms during a period when the UK government is actively seeking to support and retain fast-growing domestic enterprises.
The Capital Markets Industry Taskforce, chaired by Dame Julia Hoggett, chief executive of the London Stock Exchange, recently cautioned Chancellor Jeremy Hunt that the UK risks becoming merely an incubator for promising companies, which may eventually be acquired by foreign investors just as they reach global significance. Despite this concern, CMR and its existing investors regard the agreement as positive, emphasizing that intellectual property, research and development, manufacturing, jobs, and infrastructure will remain and expand in the UK.
Founded in 2014, CMR Surgical gained significant recognition in 2024 when its portable surgical robot, the Versius Surgical System, received regulatory approval from the U.S. Food and Drug Administration for use in adult gallbladder removal procedures. The company is actively pursuing approvals for additional applications in the U.S. market. Prior to the latest investment, CMR raised $200 million in April 2025, bringing total funding to more than $1 billion.
Among CMR’s notable investors is SoftBank, which led a $600 million funding round in 2021—the largest private funding round in the global medtech sector that year. Other investors include Tencent from China and Cambridge Innovation Capital (CIC), which collaborates with Cambridge University and regional innovation clusters to commercialize intellectual property. CIC was CMR’s first institutional investor and remains its largest British investor.
CMR maintains its headquarters and manufacturing facilities in Cambridge and employs over 500 people, approximately 400 of whom work in the UK. Chief Executive Massimiliano Colella described Stryker’s investment as a strong validation of the company’s technology, clinical achievements, and global commercial progress. The Versius system, which is designed to emulate the movements of the human arm, has become one of the most sought-after surgical robotics platforms worldwide and has been used in tens of thousands of operations.
Co-founder and former CEO Martin Frost characterized the deal as beneficial both for CMR and the UK, highlighting it as an example of fostering collaboration between a leading global medical technology company and the Cambridge innovation ecosystem.